Hong Kong-listed ophthalmic services provider C-MER Medical Holdings Limited repurchased 240,000 ordinary shares on 24 September 2026, according to its Next Day Disclosure Return filed with the Stock Exchange of Hong Kong.

The shares were acquired on-market at prices ranging between HKD 0.78 and HKD 0.80, yielding a volume-weighted average cost of HKD 0.7913 per share and an aggregate consideration of HKD 0.19 million.

Following the transaction, C-MER Medical’s outstanding share count fell from 1.20770 billion to 1.20746 billion, a 0.0199% reduction. Concurrently, the company’s treasury-share balance increased from 24.64 million to 24.88 million, keeping total issued shares unchanged at 1.23234 billion.

The purchase was made under the repurchase mandate approved on 20 May 2026, which authorises the company to buy back up to 123.23 million shares. To date, only 0.24 million shares—equivalent to 0.0195% of the share base at mandate date—have been utilised, leaving ample room for further transactions within the mandate.

In compliance with Main Board Rule 10.06, C-MER Medical is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, effective until 24 October 2026.